|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
<b>Objective:</b> The COMBI-AD trial demonstrated the efficacy and safety of dabrafenib and trametinib in combination vs placebo as adjuvant treatment of patients with BRAF V600E/K mutation-positive resected Stage IIIA (lymph node metastasis >1 mm), IIIB, or IIIC melanoma.
|
31223037 |
2019 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
<b>Objective:</b> The COMBI-AD trial demonstrated the efficacy and safety of dabrafenib and trametinib in combination vs placebo as adjuvant treatment of patients with BRAF V600E/K mutation-positive resected Stage IIIA (lymph node metastasis >1 mm), IIIB, or IIIC melanoma.
|
31223037 |
2019 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Lymph node metastasis and BRAF V600E mutations were more frequent in papillary thyroid cancers with high LOC100507661 expression.
|
27151833 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Lymph node metastasis and BRAF V600E mutations were more frequent in papillary thyroid cancers with high LOC100507661 expression.
|
27151833 |
2016 |
|
rs1800872
|
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
A promoter variant (rs1800872) in the Interleukin-10 (IL-10) gene was associated with an increased lymph node metastasis involvement [odds ratio (OR) = 2.1, 95% confidence interval (CI) = 1.03-4.2, for carriers of the TT genotype].
|
21239167 |
2011 |
|
rs531564
|
|
Secondary malignant neoplasm of lymph node
|
|
0.020 |
GeneticVariation
|
BEFREE |
Additionally, pri-miR-124 rs531564 polymorphism was significantly associated with the decreased risk of poor differentiation and lymph node metastasis of CRC.
|
26423518 |
2015 |
|
rs10754339
|
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
Additionally, the rs10754339 GG genotype was significantly associated with lymph node metastasis and PR status, and the G allele and the AG genotype were respectively associated with lymph node metastasis and ER status.
|
19903360 |
2009 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Additionally, there were significant associations (P<0.05) between BRAF(V600E) and a higher tumor-node-metastasis staging (III/IV), and between miR-21* over-expression and lymph node metastasis.
|
23416953 |
2013 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Additionally, there were significant associations (P<0.05) between BRAF(V600E) and a higher tumor-node-metastasis staging (III/IV), and between miR-21* over-expression and lymph node metastasis.
|
23416953 |
2013 |
|
rs10877887
|
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
adjusted OR = 0.50, 95% CI = 0.33-0.77, P = 0.001, respectively).Our study suggests that the rs10877887 polymorphism may be associated with the risk of PTC and the rs13293512 polymorphism may correlate to lymph node metastasis in PTC.
|
26512603 |
2015 |
|
rs13293512
|
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
adjusted OR = 0.50, 95% CI = 0.33-0.77, P = 0.001, respectively).Our study suggests that the rs10877887 polymorphism may be associated with the risk of PTC and the rs13293512 polymorphism may correlate to lymph node metastasis in PTC.
|
26512603 |
2015 |
|
rs121434569
|
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
After her death, an autopsy revealed SCLC transformation and EGFR T790M secondary mutation (T790M) as mutually exclusive resistance mechanisms occurring differently in different metastases; two liver metastases (SCLC versus AC with T790M) and two lymph node metastases (SCLC versus AC with T790M) were analyzed to compare the expression status of immune markers by immunohistochemistry and by an immune oncology gene expression panel.
|
28193529 |
2017 |
|
rs1478604
|
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
After logistic regression and stratification analysis, rs1478604 A>G was more strongly associated with lymph node metastasis in HDC gastric cancer.
|
22011138 |
2012 |
|
rs12774070
|
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
Among 141 HCC patients with smoking behaviour, we found significant associations of the rs12774070 (CC+AA vs CC) and rs61573157 (CT+TT vs CC) variants with a clinical stage of HCC (OR: 2.500 and 2.767; 95% CI: 1.148-5.446 and 1.096-6.483; P = 0.019 and 0.026, respectively) and tumour size (OR: 2.387 and 2.659; 95% CI: 1.098-5.188 and 1.055-6.704; P = 0.026 and 0.034, respectively), but not with lymph node metastasis or other clinical statuses.
|
28231306 |
2017 |
|
rs61573157
|
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
Among 141 HCC patients with smoking behaviour, we found significant associations of the rs12774070 (CC+AA vs CC) and rs61573157 (CT+TT vs CC) variants with a clinical stage of HCC (OR: 2.500 and 2.767; 95% CI: 1.148-5.446 and 1.096-6.483; P = 0.019 and 0.026, respectively) and tumour size (OR: 2.387 and 2.659; 95% CI: 1.098-5.188 and 1.055-6.704; P = 0.026 and 0.034, respectively), but not with lymph node metastasis or other clinical statuses.
|
28231306 |
2017 |
|
rs895819
|
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
Among the patients, rs895819 G variants were moderately associated with lymphatic invasion and lymph node metastasis, while rs11671784 A variants were associated with significantly reduced risk of lymphatic invasion. qRT-PCR results demonstrated rs895819 polymorphism contributed to an aberrant process from pri-miR-27a to pre-miR-27a, but rs11671784 did not affect the transcription and post-transcription processes of the miR-27a gene.
|
25399405 |
2014 |
|
rs11671784
|
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
Among the patients, rs895819 G variants were moderately associated with lymphatic invasion and lymph node metastasis, while rs11671784 A variants were associated with significantly reduced risk of lymphatic invasion. qRT-PCR results demonstrated rs895819 polymorphism contributed to an aberrant process from pri-miR-27a to pre-miR-27a, but rs11671784 did not affect the transcription and post-transcription processes of the miR-27a gene.
|
25399405 |
2014 |
|
rs74799832
|
|
Secondary malignant neoplasm of lymph node
|
|
0.020 |
GeneticVariation
|
BEFREE |
An activating M918T RET (c.2753T>C) somatic mutation was identified in a lymph node metastasis.
|
28068878 |
2017 |
|
rs438034
|
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
As a main observation, carriers of the A allele of the CENPF SNP rs438034 had a worse BC-specific survival compared to the wild type genotype GG carriers (hazard ratio (HR) 2.65, 95% confidence interval (CI) 1.19-5.90), although they were less likely to have regional lymph node metastases (odds ratio (OR) 0.71, 95% CI 0.51-1.01) and tumours of stage II-IV (OR 0.73, 95% CI 0.54-0.99).
|
19008095 |
2009 |
|
rs75873440
|
|
Secondary malignant neoplasm of lymph node
|
|
0.020 |
GeneticVariation
|
BEFREE |
Association between a SNP or haplotype and age at diagnosis or presence of lymph node metastasis was tested in 34 G533C-carries with MTC.
|
19138318 |
2009 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
|
26950846 |
2016 |
|
rs113488022
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
Association of BRAF V600E Mutation and MicroRNA Expression with Central Lymph Node Metastases in Papillary Thyroid Cancer: A Prospective Study from Four Endocrine Surgery Centers.
|
26950846 |
2016 |
|
rs11886868
|
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
BCL11A rs11886868 and rs4671393 genotype variations and correspondingly high BCL11A plasma levels are related to LSCC, besides, differences in plasma levels and genotype distribution may be related to lymph node metastasis status and the stage of LSCC.
|
28225775 |
2017 |
|
rs4671393
|
|
Secondary malignant neoplasm of lymph node
|
|
0.010 |
GeneticVariation
|
BEFREE |
BCL11A rs11886868 and rs4671393 genotype variations and correspondingly high BCL11A plasma levels are related to LSCC, besides, differences in plasma levels and genotype distribution may be related to lymph node metastasis status and the stage of LSCC.
|
28225775 |
2017 |
|
rs121913377
|
|
Secondary malignant neoplasm of lymph node
|
|
0.100 |
GeneticVariation
|
BEFREE |
BRAF V600E mutation and p27 kip1 expression in papillary carcinomas of the thyroid <or=1 cm and their paired lymph node metastases.
|
17685465 |
2007 |